Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 21;34(6):108728. doi: 10.1016/j.celrep.2021.108728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Longitudinal analysis of SARS-CoV-2-specific antibody-related responses in acute COVID-19 patients

(A) Schematic representation of the surrogate virus neutralization assay and the Luminex-based assay to quantify SARS-CoV-2 RBD-, S1-, and NP-specific IgG and IgM antibodies. Cutoffs to define significant virus neutralization and antibody quantities were set at 20% inhibition for the sVNT assay (as defined in ref (Tan et al., 2020)) and MFI (mean fluorescence intensity) > 100 for the Luminex-based assay, respectively.

(B) SARS-CoV-2 neutralization and relative quantities of specific IgG and antibodies (n = 12).

(C) Rose plots represent the quantity of RBD-, S1-, and NP-specific IgG and IgM antibodies at first detectable antibody response (n = 12). Patient P02 had no detectable antibody response at 3, 4, 7, and 9 days after symptom onset for which samples were available.